Literature DB >> 9506376

Prevalence of HSV-2 antibodies among STD clinic patients in Tanzania.

N Langeland1, L Haarr, F Mhalu.   

Abstract

Patients attending a referral sexually transmissible diseases clinic at Muhimbili Medical Centre in Dar-es-Salaam during the period 1989 to 1993 were examined for herpes simplex virus type 2 (HSV-2) antibodies. An ELISA technique, using glycoprotein G of HSV-2 as antigen, was used to test 294 patients' sera. Of these, 126 sera were HSV-2 positive, while 168 were negative, yielding an overall HSV-2 prevalence of 42.9%. Sixty-three per cent of the women and 35.5% of the men were HSV-2 positive. Seropositivity rose from 8.7% in the youngest men to 61.5% in the oldest male age group, while even the youngest women aged 20 or less had an HSV-2 prevalence of 55.6%. There was a significant positive association between HIV and HSV-2 seropositivity (P=0.0006), most pronounced among the youngest women. There was no over-representation of HSV-2 positivity among patients with genital ulcer disease, indicating that other causes of this disease could be more common than HSV-2 in Tanzania.

Entities:  

Keywords:  Africa; Africa South Of The Sahara; Antibodies; Biology; Clients; Delivery Of Health Care; Developing Countries; Diseases; Eastern Africa; English Speaking Africa; Health; Health Facilities; Herpes Genitalis; Hiv Infections; Immunity; Immunologic Factors; Infections; Measurement; Organization And Administration; Outpatient Clinic; Physiology; Prevalence; Program Activities; Programs; Reproductive Tract Infections; Research Methodology; Research Report; Sexually Transmitted Diseases; Tanzania; Viral Diseases

Mesh:

Substances:

Year:  1998        PMID: 9506376     DOI: 10.1258/0956462981921765

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  9 in total

Review 1.  Increasing prevalence of genital herpes in developing countries: implications for heterosexual HIV transmission and STI control programmes.

Authors:  N O'Farrell
Journal:  Sex Transm Infect       Date:  1999-12       Impact factor: 3.519

2.  Prevalence of antibodies against herpes simplex virus types 1 and 2 in children and young people in an urban region in Tanzania.

Authors:  Mabula Joseph Kasubi; Arvid Nilsen; Howard S Marsden; Tomas Bergström; Nina Langeland; Lars Haarr
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

3.  Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2.

Authors:  Ramzi A Alsallaq; Joshua T Schiffer; Ira M Longini; Anna Wald; Lawrence Corey; Laith J Abu-Raddad
Journal:  Sex Transm Dis       Date:  2010-05       Impact factor: 2.830

4.  Mature glycoprotein g presents high performance in diagnosing herpes simplex virus type 2 infection in sera of different tanzanian cohorts.

Authors:  Staffan Görander; Judica Mbwana; Eligius Lyamuya; Teresa Lagergård; Jan-Ake Liljeqvist
Journal:  Clin Vaccine Immunol       Date:  2006-06

5.  Serological Profile of HSV-2 in STD Patients: Evaluation of Diagnostic Utility of HSV-2 IgM and IgG Detection.

Authors:  V P Amudha; G Sucilathangam; B Cinthujah; C Revathy
Journal:  J Clin Diagn Res       Date:  2014-12-05

6.  Prevalence of infection with herpes simplex virus types 1 and 2 in Australia: a nationwide population based survey.

Authors:  A L Cunningham; R Taylor; J Taylor; C Marks; J Shaw; A Mindel
Journal:  Sex Transm Infect       Date:  2006-04       Impact factor: 3.519

Review 7.  [Herpes simplex virus infections].

Authors:  G Gross
Journal:  Hautarzt       Date:  2004-09       Impact factor: 0.751

8.  HSV type specific serology in sexual health clinics: use, benefits, and who gets tested.

Authors:  B Song; D E Dwyer; A Mindel
Journal:  Sex Transm Infect       Date:  2004-04       Impact factor: 3.519

9.  Sexual risk factors for HIV infection in early and advanced HIV epidemics in sub-Saharan Africa: systematic overview of 68 epidemiological studies.

Authors:  Li Chen; Prabhat Jha; Bridget Stirling; Sema K Sgaier; Tina Daid; Rupert Kaul; Nico Nagelkerke
Journal:  PLoS One       Date:  2007-10-03       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.